Human Vaccines & Immunotherapeutics
Volume 8, 2012 - Issue 10
Reprints and Corporate Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
To request a reprint or corporate permissions for this article, please click on the relevant link below:
Academic Permissions
Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?
Obtain permissions instantly via Rightslink by clicking on the button below:
If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.
Related Research Data
Peptide immunotherapy for allergic diseases
Source:
Wiley
The safety and efficacy of ALLERVAX CAT in cat allergic patients.
Source:
Elsevier BV
Vaccination with genetically engineered allergens prevents progression of allergic disease
Source:
Proceedings of the National Academy of Sciences
Mechanisms of allergen-specific desensitization
Source:
Elsevier
A Novel Approach to Specific Allergy Treatment: The Recombinant Fusion Protein of a Bacterial Cell Surface (S-Layer) Protein and the Major Birch Pollen Allergen Bet v 1 (rSbsC-Bet v 1) Combines Reduced Allergenicity with Immunomodulating Capacity
Source:
The American Association of Immunologists
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults.
Source:
Elsevier BV
Peptide and recombinant immunotherapy.
Source:
Elsevier BV
Non‐anaphylactic surface‐exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination
Source:
Wiley
Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy.
Source:
Wiley-Blackwell
IgE-binding epitopes
Source:
Wiley
Application of multiplexed immunoglobulin E determination on a chip in component-resolved diagnostics in allergy.
Source:
Wiley
Immunotherapy with peptides
Source:
Wiley
Component resolved testing for allergic sensitization.
Source:
Springer Science and Business Media LLC
Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis
Source:
Elsevier BV
Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy
Source:
Springer Nature
Sequence analysis of cDNA coding for a major house dust mite allergen, Der p 1. Homology with cysteine proteases.
Source:
Rockefeller University Press
Prevention of new sensitizations
Source:
Wiley
History of allergen-specific immunotherapy
Source:
Wiley
Studies on allergoids from naturally occurring allergens III. Preparation of ragweed pollen allergoids by aldehyde modification in two steps
Source:
Elsevier BV
Pollen-food syndromes associated with weed pollinosis: an update from the molecular point of view.
Source:
Wiley
CRD and CRIT
Source:
Wiley
Recombinant allergen fragments as candidate preparations for allergen immunotherapy
Source:
Elsevier BV
Allergen-specific immunotherapy with recombinant grass pollen allergens.
Source:
Elsevier BV
A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination.
Source:
Elsevier BV
Vaccination with genetically modified birch pollen allergens: Immune and clinical effects on oral allergy syndrome
Source:
Elsevier BV
Recombinant allergen-based immunotherapy
Source:
Wiley
Recombinant allergens: What does the future hold?
Source:
Elsevier BV
Standardized allergen extracts: past, present and future
Source:
Informa UK Limited
Safety and Tolerability of Recombinant Bet v 1 (rBet v 1) Tablets in Sublingual Immunotherapy (SLIT)
Source:
Elsevier BV
Treatment of cat allergy with T-cell reactive peptides.
Source:
American Thoracic Society
Cloning and expression of DNA coding for the major house dust mite allergen Der p 1 in Escherichia coli.
Source:
S. Karger AG
Future forms of immunotherapy
Source:
Elsevier BV
Linking provided by
